Learn what sets Bethyl custom monoclonal antibodies quality and service apart and discover the top reasons why you should choose Forits Life Sciences for your next project.
List view / Grid view
The latest ebook from Sartorius takes an in-depth look at the technologies and techniques that have been integral to developing the antibody discovery workflow, featuring a host of expert articles, interviews and application notes.
With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe…
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.
A new study has shown that previous coronavirus infection may contribute to the immune response of patients infected with SARS-CoV-2.
By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
Researchers have shown that neutralising antibodies developed in COVID-19 patients were less potent if from those with severe or fatal disease.
Engineered deubiquitinases combines a synthetic nanobody that recognises a protein that can rescue proteins tagged for destruction.
Researchers have said that more COVID-19 studies should focus on the mucous membranes of the nose and mouth, to reveal insights into SARS-CoV-2 immunity.
A study in healthcare workers has shown that antibodies from COVID-19 infection protect individuals from reinfection for at least six months.
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
UKRI will provide £4 million in funding to establish a data infrastructure for scientists in the UK to study antibodies from COVID-19 patient samples.
Scientists have developed a new antibody-drug conjugate (ADC), made from ICAM1, an antibody that targets pancreatic cancer and the cytotoxic drug DM1 (mertansine).